Overview
- Novo Nordisk began selling most Wegovy and Ozempic doses to cash‑pay patients for $349 per month, with Ozempic’s 2 mg dose remaining $499.
- New cash‑pay patients can access the two lowest doses for $199 per month for the first two months, with the introductory offer running through March 31, 2026.
- The offers are available immediately via Wegovy.com, Ozempic.com, NovoCare, and partners including GoodRx, Costco, WeightWatchers, select telehealth providers, and more than 70,000 pharmacies.
- The move precedes the White House’s TrumpRx direct‑to‑consumer channel and negotiated government pricing, which are set to start in 2026 with injectables targeted near $245 for Medicare/Medicaid and potential $149 starter prices for pills if approved.
- Eli Lilly’s competing Zepbound is priced for cash‑pay at $299 for the lowest dose and up to $449 for higher doses, while clinicians caution that even the new Novo prices may remain out of reach for many without insurance.